← Back to patent-cliff list
Temuterkib mesylate
Tier C — Watch / tradeTemuterkib mesylate
Eli Lilly and Company
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ERK1, ERK2
Indications (approved)：Bile duct cancer, Non-small cell lung cancer, Colorectal cancer, Ovarian cancer, Pancreatic cancer, Endometrial cancer, Cholangiocarcinoma, Peritoneal cancer
Regional status
US
Phase II
2020-05-27
EU
Phase II
2021-07-19
China
-
Japan
Phase II
2021-07-19
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Temuterkib mesylate?
Approved indications include: Bile duct cancer, Non-small cell lung cancer, Colorectal cancer, Ovarian cancer, Pancreatic cancer, Endometrial cancer, Cholangiocarcinoma, Peritoneal cancer.
When does the Temuterkib mesylate patent expire?
No public expiry year is available for Temuterkib mesylate yet; this page updates once verified.
How do I get a quote for Temuterkib mesylate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22